Ready? We celebrate the #ETPN20years with lots of new activities. Are you an early career researcher? we have organized a session just for you, don’t miss the ETPN Academy with tips and tricks to boost your career.
#NME25#Nanomedicine#HealthTech https://t.co/U3UB3jhLRt
Open Virtual Meeting on ISEV new Task Force for EV-TRACK March 29th - https://t.co/CbgOrV0mDw -
The diversity and rapid evolution of the EV research field, requieres co-evolution of EV-TRACK to ensure continued coaching of researchers in transparent reporting, systematic cat...
Happy to share our latest work @ACSPublications from @RappsilberLab@adambelsom@RappsilberJuri A catalytic peptide to mediate bioorthogonal chemistry by synthesizing two anticancer drugs: paclitaxel and linifanib in lung cancer cells. https://t.co/0AKjU3mw9e
So happy to be part of this inspirational campaign @ies_rosginer for the #InternationalWomensDay2022 Hoping many more women join us in science.
https://t.co/QlWgyxoJb0
Interested in the chemistry behind approved kinase inhibitors? Check out the comprehensive perspective in Journal of Medicinal Chemistry by @BOOMchemistry here:
https://t.co/xl5hhaKgvJ
If you are interested in drug discovery and want to know more about all the approved small molecule kinase inhibitors, their medical indication, pharmacology and original synthesis, check out our last perspective! @ACSBioMed@EdinUni_IGC@BOOMchemistry
https://t.co/mDDZCkdoha
Interested in the discovery process of approved kinase inhibitors? Check out the chemistry behind, in our comprehensive perspective @BOOMchemistry@EdinCRC https://t.co/VzHBBu1gKj
Would you like to know why SRC/YES1 inhibitor discovered by our researchers @EdinCRC@EdinUni_IGC@EdinburghUni and expected to commence studies to secure approval to conduct the first-in-human clinical trials is so unique? Read the story on our website: https://t.co/lFJi0E9BvB
10 years of research culminates with this work. Our most important contribution to the cancer field. Joint effort from @EdinCRC, @MRC_CRH and @CIB_CSIC!! https://t.co/Ih9SrFi44w
SRC/YES1 inhibitor discovered by our researchers has been licensed to Nuvectis Pharma, Inc.! This inhibitor has new mechanism of action and might result in better treatments in the future. Read more on the Scottish Business News website 👇:
https://t.co/WfH0IAVnuq
SRC/YES1 inhibitor discovered by our researchers has been licensed to Nuvectis Pharma, Inc.! This inhibitor has new mechanism of action and might result in better treatments in the future. Read more on the Scottish Business News website 👇:
https://t.co/WfH0IAVnuq
Se percibe un desvanecimiento de la necesidad de cuestionar y transformar las condiciones sociales que producen problemáticas que son las que precisamente demandan respuestas de resiliencia...
resiliencia de la resiliencia
💉¿Puedo seguir contagiando después de vacunarme de la #COVID-19? ¡La gran pregunta!
🔦Intentamos arrojar algo de luz con @SEinmunologia y esta #ilustración!
Detalles en el #hilo 👇
Gracias a África González, Marcos Hoyos, @Jesus_BTC y @arlosdel por sus aportaciones!!
#Researchers and #Policy-makers work in partnership in many crucial fields, such as #Cancer.
If you want to contribute to the 🇪🇺 debate on #CancerResearch, join the #MSCA cluster event!
Together we can find solutions👍
Register now➡️https://t.co/TCIORW49lQ
#MissionCancer